{"id":477951,"date":"2020-04-06T12:30:01","date_gmt":"2020-04-06T12:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477951"},"modified":"2020-04-06T12:30:01","modified_gmt":"2020-04-06T12:30:01","slug":"postherpetic-neuralgia-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/postherpetic-neuralgia-pipeline-insight-2020_477951.html","title":{"rendered":"Postherpetic Neuralgia Pipeline Insight, 2020"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on&nbsp;Postherpetic Neuralgia Pipeline Insight, 2020<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Postherpetic Neuralgia Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Postherpetic Neuralgia&nbsp;market. A detailed picture of the&nbsp;Postherpetic Neuralgia&nbsp;pipeline landscape is provided, which includes the disease overview and&nbsp;Postherpetic Neuralgia&nbsp;treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;Postherpetic Neuralgia&nbsp;commercial assessment and clinical assessment of the&nbsp;Postherpetic Neuralgia&nbsp;pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;Postherpetic Neuralgia&nbsp;collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/2cdf18ace43035c5e6efd6268e8c873b.JPG\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><em><strong>Request for :- <\/strong><\/em><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/postherpetic-neuralgia-pipeline-insight\" target=\"_blank\">PHN free sample page<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Pipeline Development Activities:-&nbsp;<\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>The report provides insights into:&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span>All of the companies that are developing therapies for the treatment of&nbsp;<\/span><span>Postherpetic Neuralgia&nbsp;<\/span><span>with aggregate therapies developed by each company for the same.<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;<\/span><span>Postherpetic Neuralgia<\/span><span>&nbsp;treatment.<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Postherpetic Neuralgia&nbsp;<\/span><span>key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;<\/span><span>Postherpetic Neuralgia<\/span><span>&nbsp;market.<\/span><\/li>\n<\/ul>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Report Scope:-&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\"><span>The&nbsp;<\/span><span>Postherpetic Neuralgia&nbsp;<\/span><span>report provides an overview of&nbsp;<\/span><em>therapeutic pipeline activity and therapeutic assessment of the products<\/em><span>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<\/span><em>for&nbsp;<\/em><span>Postherpetic Neuralgia&nbsp;<\/span><span>across the complete product development cycle, including all clinical and nonclinical stages.<\/span><\/li>\n<li class=\"ql-align-justify\"><span>It comprises of&nbsp;<\/span><em>detailed profiles of&nbsp;<\/em><span>Postherpetic Neuralgia&nbsp;<\/span><em>therapeutic products<\/em><span>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Detailed&nbsp;<\/span><span>Postherpetic Neuralgia&nbsp;<\/span><em>research and development progress and trial details<\/em><span>, results wherever available, are also included in the pipeline study.<\/span><\/li>\n<li class=\"ql-align-justify\"><em>Coverage of dormant and discontinued pipeline project<\/em><span>s along with the reasons if available across&nbsp;<\/span><span>Postherpetic Neuralg.<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em><strong>Report Highlights:-&nbsp;<\/strong><\/em><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">A better understanding of disease pathogenesis contributing to the development of novel therapeutics for&nbsp;Postherpetic Neuralgia.&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<li class=\"ql-align-justify\">In the coming years, the&nbsp;<span>Postherpetic Neuralgia&nbsp;<\/span>market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/li>\n<li class=\"ql-align-justify\"><span>The companies and academics that are working to assess challenges and seek opportunities that could influence&nbsp;<\/span><span>Postherpetic Neuralgia&nbsp;<\/span><span>R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/span><\/li>\n<li class=\"ql-align-justify\">A detailed portfolio of major pharma players who are involved in fueling the&nbsp;<span>Postherpetic Neuralgia&nbsp;<\/span><span>treatment market<\/span>. Several potential therapies for&nbsp;<span>Postherpetic Neuralgia&nbsp;<\/span>are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the&nbsp;<span>Postherpetic Neuralgia&nbsp;<\/span>market size in the coming years.&nbsp;&nbsp;<\/li>\n<li class=\"ql-align-justify\">Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of&nbsp;<span>Postherpetic Neuralgia<\/span>) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em><strong>Key companies are working PHN are given below:-&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><em><strong>1. <\/strong>Lateral Pharma Co.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><em>2. Novartis Pharma Co&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><em>3. TEVA Pharma Co.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><em><strong>Name of drugs covered that are given below:-<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><em>1. LAT 8881<\/em><\/p>\n<p style=\"text-align: justify;\"><em>2. EMA 401<\/em><\/p>\n<p style=\"text-align: justify;\"><em>3. TV 45070<\/em><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/delveinsight.com\/report-store\/postherpetic-neuralgia-pipeline-insight#curriculum\" target=\"_blank\">Table of contents<\/a><\/p>\n<p style=\"text-align: justify;\"><span>1. Report Introduction<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Postherpetic Neuralgia&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.1. Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.2. History&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.3. Postherpetic Neuralgia Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.4. Causes<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.5.Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6. Postherpetic Neuralgia Diagnosis&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>2.6.1. Diagnostic Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Postherpetic Neuralgia&nbsp;Current Treatment Patterns<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Postherpetic Neuralgia Treatment Guidelines<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Postherpetic Neuralgia&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1. In-depth Commercial Assessment<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>4.1.1. Postherpetic Neuralgia&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6. Postherpetic Neuralgia Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\"><span>7. Postherpetic Neuralgia Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Postherpetic Neuralgia Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Postherpetic Neuralgia&nbsp;Product Profiles<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14. Postherpetic Neuralgia&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\"><span>15. Postherpetic Neuralgia&nbsp;Key Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Dormant and Discontinued Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1. Dormant Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1.1. Reasons for being dormant<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2. Discontinued Products&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.2.1. Reasons for the discontinuation<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. Postherpetic Neuralgia&nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Postherpetic Neuralgia&nbsp;Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Postherpetic Neuralgia&nbsp;Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. Report Methodology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.1. Secondary Research<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.2. Expert Panel Validation&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><strong><em>22. About<\/em><\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">Delveinsight<\/a><\/p>\n<p style=\"text-align: justify;\"><strong><em>Related Reports:-&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">1.&nbsp;<a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/delveinsight.com\/report-store\/postherpetic-neuralgia-epidemiology-forecast\">Postherpetic Neuralgia &#8211; Epidemiology Forecast to 2030<\/a><\/p>\n<p style=\"text-align: justify;\">2.&nbsp;<a rel=\"nofollow\" class=\"h6 title fs-11\" href=\"https:\/\/delveinsight.com\/report-store\/postherpetic-neuralgia-market\">Postherpetic Neuralgia- Market Insight, Epidemiology and Market Forecast -2030<\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=postherpetic-neuralgia-pipeline-insight-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=postherpetic-neuralgia-pipeline-insight-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight has launched a new report on&nbsp;Postherpetic Neuralgia Pipeline Insight, 2020 &#8220;Postherpetic Neuralgia Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Postherpetic Neuralgia&nbsp;market. A detailed picture of the&nbsp;Postherpetic Neuralgia&nbsp;pipeline landscape &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/postherpetic-neuralgia-pipeline-insight-2020_477951.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[417,406],"tags":[],"class_list":["post-477951","post","type-post","status-publish","format-standard","hentry","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477951"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477951\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}